나오성

나오성 (chief executive) discloses dealings in 에이프로젠바이오로직스 to DART (FSS). We count 3 filings; the first trade dates from 24 May 2024 and the latest from 15 April 2026.

In open-market terms, that means 1 purchase on one side and 2 sales on the other. The amount is not disclosed for 3 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2026: no purchases and 1 sale on the market.

The latest filing, published on 8 May 2026, reports an open-market sale in 에이프로젠바이오로직스. The last purchase on record was published on 31 May 2024, which is 893 days ago. Between a trade and the moment it shows up on DART (FSS), the median delay is 7 days. This delay matters because a trade only becomes useful information once it is public. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.